JACQUES THEURILLAT

Jacques Theurillat is a distinguished Partner at Sofinnova Partners, a globally recognized European venture capital firm with a rich history of investing in life sciences. His strategic vision and deep industry expertise are pivotal in advancing Sofinnova's mission to support groundbreaking scientific innovation that addresses unmet medical needs.

As a Partner, Jacques plays a critical role in the firm's investment strategy, particularly within the dynamic sectors of biotechnology, pharmaceuticals, and cutting-edge medical technologies. He is actively involved in sourcing new investment opportunities, conducting thorough due diligence, and leading investment rounds for promising startups and growth-stage companies. His focus often spans novel therapeutic platforms, innovative drug discovery, and disruptive medical devices designed to improve patient outcomes. Jacques also provides invaluable guidance and strategic oversight to portfolio companies, often serving on their boards, helping them navigate complex development pathways from preclinical stages through to commercialization.

While specific details of Jacques Theurillat's early career are not publicly detailed, his trajectory to Partner at Sofinnova Partners suggests a robust background in life sciences, finance, or a combination thereof. Typically, individuals in such senior roles possess extensive experience in scientific research, clinical development, corporate development within pharmaceutical or biotech companies, or a strong track record in venture capital or investment banking focused on the healthcare sector. This foundational expertise equips him with a profound understanding of the scientific, regulatory, and commercial challenges inherent in the life sciences industry, enabling him to identify truly transformative opportunities.

Sofinnova Partners has a long history of successful investments across Europe and globally, contributing to the development of numerous blockbuster drugs and medical technologies. While specific individual investments led by Jacques Theurillat are not explicitly listed, his involvement as a Partner means he contributes to the firm's overall portfolio success. Sofinnova's portfolio typically includes companies developing novel oncology treatments, gene therapies, rare disease solutions, and advanced digital health platforms. Jacques' contributions are integral to identifying and scaling companies that have the potential to significantly impact patient lives and generate substantial returns for investors. His work helps solidify Sofinnova's reputation as a leader in life sciences venture capital.

Jacques Theurillat's dedication to fostering innovation and his strategic acumen make him a key figure at Sofinnova Partners, driving forward investments that promise to redefine healthcare and improve human well-being.